Zacks Investment Research upgraded shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) from a sell rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
Other research analysts also recently issued research reports about the company. Credit Suisse Group upgraded Corvus Pharmaceuticals from an underperform rating to a neutral rating and set a $14.00 price objective for the company in a research note on Wednesday, August 23rd. Wedbush restated an outperform rating and issued a $26.00 price objective on shares of Corvus Pharmaceuticals in a research note on Tuesday, August 8th. Finally, Cowen and Company restated an outperform rating on shares of Corvus Pharmaceuticals in a research note on Tuesday, July 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $20.75.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03.
COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/2957948/corvus-pharmaceuticals-inc-crvs-lifted-to-hold-at-zacks-investment-research.html.
Large investors have recently made changes to their positions in the business. TIAA CREF Investment Management LLC grew its stake in Corvus Pharmaceuticals by 43.3% in the 1st quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock valued at $149,000 after purchasing an additional 2,170 shares during the period. Russell Investments Group Ltd. grew its stake in Corvus Pharmaceuticals by 29.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after purchasing an additional 2,105 shares during the period. New York State Common Retirement Fund grew its stake in Corvus Pharmaceuticals by 2,269.1% in the 2nd quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after purchasing an additional 9,099 shares during the period. Endurant Capital Management LP bought a new position in Corvus Pharmaceuticals in the 1st quarter valued at $282,000. Finally, Oxford Asset Management bought a new position in Corvus Pharmaceuticals in the 1st quarter valued at $287,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.